Found: 107
Select item for more details and to access through your institution.
A decision-theoretic phase I-II design for ordinal outcomes in two cycles.
- Published in:
- 2016
- By:
- Publication type:
- journal article
A phase I-II design based on periodic and continuous monitoring of disease status and the times to toxicity and death.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Monitoring late-onset toxicities in phase I trials using predicted risks.
- Published in:
- 2008
- By:
- Publication type:
- journal article
Monitoring late-onset toxicities in phase I trials using predicted risks.
- Published in:
- Biostatistics, 2008, v. 9, n. 3, p. 442, doi. 10.1093/biostatistics/kxm044
- By:
- Publication type:
- Article
Monitoring late-onset toxicities in phase I trials using predicted risks.
- Published in:
- Biostatistics, 2008, v. 9, n. 3, p. 442, doi. 10.1093/biostatistics/kxm044
- By:
- Publication type:
- Article
Bayesian treatment comparison using parametric mixture priors computed from elicited histograms.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Ethical issues in oncology biostatistics.
- Published in:
- 2002
- By:
- Publication type:
- journal article
Two-stage selection and testing designs for comparative clinical trials.
- Published in:
- Biometrika, 1988, v. 75, n. 2, p. 303
- By:
- Publication type:
- Article
A generalized outcome-adaptive sequential multiple assignment randomized trial design.
- Published in:
- Biometrics, 2024, v. 80, n. 3, p. 1, doi. 10.1093/biomtc/ujae073
- By:
- Publication type:
- Article
A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparison.
- Published in:
- Biometrics, 2024, v. 80, n. 1, p. 1, doi. 10.1093/biomtc/ujad022
- By:
- Publication type:
- Article
Bayesian treatment screening and selection using subgroup‐specific utilities of response and toxicity.
- Published in:
- Biometrics, 2023, v. 79, n. 3, p. 2458, doi. 10.1111/biom.13738
- By:
- Publication type:
- Article
Bayesian group sequential enrichment designs based on adaptive regression of response and survival time on baseline biomarkers.
- Published in:
- Biometrics, 2022, v. 78, n. 1, p. 60, doi. 10.1111/biom.13421
- By:
- Publication type:
- Article
An adaptive trial design to optimize dose‐schedule regimes with delayed outcomes.
- Published in:
- Biometrics, 2020, v. 76, n. 1, p. 304, doi. 10.1111/biom.13116
- By:
- Publication type:
- Article
A hybrid phase I‐II/III clinical trial design allowing dose re‐optimization in phase III.
- Published in:
- Biometrics, 2019, v. 75, n. 2, p. 371, doi. 10.1111/biom.12994
- By:
- Publication type:
- Article
Rejoinder to "A hybrid phase I‐II/III clinical trial design allowing dose reoptimization in phase III".
- Published in:
- Biometrics, 2019, v. 75, n. 2, p. 389, doi. 10.1111/biom.12991
- By:
- Publication type:
- Article
A utility‐based design for randomized comparative trials with ordinal outcomes and prognostic subgroups.
- Published in:
- Biometrics, 2018, v. 74, n. 3, p. 1095, doi. 10.1111/biom.12842
- By:
- Publication type:
- Article
Bayesian nonparametric estimation of targeted agent effects on biomarker change to predict clinical outcome.
- Published in:
- Biometrics, 2015, v. 71, n. 1, p. 188, doi. 10.1111/biom.12250
- By:
- Publication type:
- Article
Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule-Dose Regimes.
- Published in:
- Biometrics, 2013, v. 69, n. 3, p. 673, doi. 10.1111/biom.12065
- By:
- Publication type:
- Article
Optimizing the Concentration and Bolus of a Drug Delivered by Continuous Infusion.
- Published in:
- Biometrics, 2011, v. 67, n. 4, p. 1638, doi. 10.1111/j.1541-0420.2011.01580.x
- By:
- Publication type:
- Article
Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials.
- Published in:
- Biometrics, 2010, v. 66, n. 2, p. 532, doi. 10.1111/j.1541-0420.2009.01302.x
- By:
- Publication type:
- Article
Patient-Specific Dose Finding Based on Bivariate Outcomes and Covariates.
- Published in:
- Biometrics, 2008, v. 64, n. 4, p. 1126, doi. 10.1111/j.1541-0420.2008.01009.x
- By:
- Publication type:
- Article
Determining the Effective Sample Size of a Parametric Prior.
- Published in:
- Biometrics, 2008, v. 64, n. 2, p. 595, doi. 10.1111/j.1541-0420.2007.00888.x
- By:
- Publication type:
- Article
A Geometric Approach to Comparing Treatments for Rapidly Fatal Diseases.
- Published in:
- Biometrics, 2006, v. 62, n. 1, p. 193, doi. 10.1111/j.1541-0420.2005.00434.x
- By:
- Publication type:
- Article
Determining a Maximum-Tolerated Schedule of a Cytotoxic Agent.
- Published in:
- Biometrics, 2005, v. 61, n. 2, p. 335, doi. 10.1111/j.1541-0420.2005.00312.x
- By:
- Publication type:
- Article
Dose-Finding Based on Efficacy–Toxicity Trade-Offs.
- Published in:
- Biometrics, 2004, v. 60, n. 3, p. 684, doi. 10.1111/j.0006-341X.2004.00218.x
- By:
- Publication type:
- Article
Dose-Finding with Two Agents in Phase I Oncology Trials.
- Published in:
- Biometrics, 2003, v. 59, n. 3, p. 487, doi. 10.1111/1541-0420.00058
- By:
- Publication type:
- Article
Seamlessly Expanding a Randomized Phase II Trial to Phase III.
- Published in:
- Biometrics, 2002, v. 58, n. 4, p. 823, doi. 10.1111/j.0006-341X.2002.00823.x
- By:
- Publication type:
- Article
Adaptive Decision Making in a Lymphocyte Infusion Trial.
- Published in:
- Biometrics, 2002, v. 58, n. 3, p. 560, doi. 10.1111/j.0006-341X.2002.00560.x
- By:
- Publication type:
- Article
Monitoring the Rates of Composite Events with Censored Data in Phase II Clinical Trials.
- Published in:
- Biometrics, 2002, v. 58, n. 1, p. 89, doi. 10.1111/j.0006-341X.2002.00089.x
- By:
- Publication type:
- Article
Decision-Theoretic Designs for Pre-Phase II Screening Trials in Oncology.
- Published in:
- Biometrics, 2001, v. 57, n. 4, p. 1089, doi. 10.1111/j.0006-341X.2001.01089.x
- By:
- Publication type:
- Article
Dose-Finding Based on Feasibility and Toxicity in T-cell Infusion Trials.
- Published in:
- Biometrics, 2001, v. 57, n. 3, p. 914, doi. 10.1111/j.0006-341X.2001.00914.x
- By:
- Publication type:
- Article
Approximate Bayesian Evaluation of Multiple Treatment Effects.
- Published in:
- Biometrics, 2000, v. 56, n. 1, p. 213, doi. 10.1111/j.0006-341X.2000.00213.x
- By:
- Publication type:
- Article
Treatment Comparisons Based on Two-Dimensional Safety and Efficacy Alternatives in Oncology Trials.
- Published in:
- Biometrics, 1999, v. 55, n. 3, p. 746, doi. 10.1111/j.0006-341X.1999.00746.x
- By:
- Publication type:
- Article
Decision Theoretic Designs for Phase II Clinical Trials with Multiple Outcomes.
- Published in:
- Biometrics, 1999, v. 55, n. 3, p. 971, doi. 10.1111/j.0006-341X.1999.00971.x
- By:
- Publication type:
- Article
Response.
- Published in:
- 2008
- By:
- Publication type:
- Letter
Adaptive Therapy for Androgen-Independent Prostate Cancer: A Randomized Selection Trial of Four Regimens.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2007, v. 99, n. 21, p. 1613, doi. 10.1093/jnci/djm189
- By:
- Publication type:
- Article
Interpreting Randomized Controlled Trials.
- Published in:
- Cancers, 2023, v. 15, n. 19, p. 4674, doi. 10.3390/cancers15194674
- By:
- Publication type:
- Article
A Causal Framework for Making Individualized Treatment Decisions in Oncology.
- Published in:
- Cancers, 2022, v. 14, n. 16, p. 3923, doi. 10.3390/cancers14163923
- By:
- Publication type:
- Article
Making Patient-Specific Treatment Decisions Using Prognostic Variables and Utilities of Clinical Outcomes.
- Published in:
- Cancers, 2021, v. 13, n. 11, p. 2741, doi. 10.3390/cancers13112741
- By:
- Publication type:
- Article
Adverse Event Burden Score—A Versatile Summary Measure for Cancer Clinical Trials.
- Published in:
- Cancers, 2020, v. 12, n. 11, p. 3251, doi. 10.3390/cancers12113251
- By:
- Publication type:
- Article
A review of phase 2-3 clinical trial designs.
- Published in:
- 2008
- By:
- Publication type:
- journal article
Clinical trial design as a decision problem.
- Published in:
- Applied Stochastic Models in Business & Industry, 2017, v. 33, n. 3, p. 296, doi. 10.1002/asmb.2222
- By:
- Publication type:
- Article
Generalized phase I‐II designs to increase long term therapeutic success rate.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 4, p. 692, doi. 10.1002/pst.2301
- By:
- Publication type:
- Article
A Bayesian piecewise exponential phase II design for monitoring a time‐to‐event endpoint.
- Published in:
- Pharmaceutical Statistics, 2023, v. 22, n. 1, p. 34, doi. 10.1002/pst.2256
- By:
- Publication type:
- Article
Comparing Bayesian early stopping boundaries for phase II clinical trials.
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 6, p. 928, doi. 10.1002/pst.2046
- By:
- Publication type:
- Article
Subgroup‐specific dose finding in phase I clinical trials based on time to toxicity allowing adaptive subgroup combination.
- Published in:
- Pharmaceutical Statistics, 2018, v. 17, n. 6, p. 734, doi. 10.1002/pst.1891
- By:
- Publication type:
- Article
Bayesian nonparametric statistics: A new toolkit for discovery in cancer research.
- Published in:
- Pharmaceutical Statistics, 2017, v. 16, n. 6, p. 414, doi. 10.1002/pst.1819
- By:
- Publication type:
- Article
A simulation study of methods for selecting subgroup-specific doses in phase 1 trials.
- Published in:
- Pharmaceutical Statistics, 2017, v. 16, n. 2, p. 143, doi. 10.1002/pst.1797
- By:
- Publication type:
- Article
Expression of Bcl‐2 in gastrointestinal stromal tumors: Correlation with progression‐free survival in 81 patients treated with imatinib mesylate.
- Published in:
- Cancer (0008543X), 2006, v. 106, n. 7, p. 1617
- By:
- Publication type:
- Article
Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma.
- Published in:
- Cancer (0008543X), 2003, v. 97, n. 3, p. 561, doi. 10.1002/cncr.11078
- By:
- Publication type:
- Article